Utah Retirement Systems grew its stake in Juno Therapeutics, Inc. (NASDAQ:JUNO) by 1.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,600 shares of the biopharmaceutical company’s stock after acquiring an additional 200 shares during the period. Utah Retirement Systems’ holdings in Juno Therapeutics were worth $347,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. M&T Bank Corp bought a new position in Juno Therapeutics in the 1st quarter worth about $381,000. Nisa Investment Advisors LLC purchased a new stake in shares of Juno Therapeutics in the 1st quarter worth approximately $200,000. Laurion Capital Management LP purchased a new stake in shares of Juno Therapeutics in the 1st quarter worth approximately $390,000. Marshall Wace LLP purchased a new stake in shares of Juno Therapeutics in the 2nd quarter worth approximately $1,071,000. Finally, BB Biotech AG lifted its position in shares of Juno Therapeutics by 16.8% in the 1st quarter. BB Biotech AG now owns 2,185,000 shares of the biopharmaceutical company’s stock worth $48,485,000 after purchasing an additional 315,000 shares during the period. Institutional investors and hedge funds own 70.76% of the company’s stock.
In other Juno Therapeutics news, General Counsel Bernard J. Cassidy sold 28,000 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $44.92, for a total transaction of $1,257,760.00. Following the completion of the transaction, the general counsel now owns 55,970 shares in the company, valued at approximately $2,514,172.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Anthony B. Evnin purchased 9,000 shares of the stock in a transaction on Tuesday, June 20th. The shares were purchased at an average price of $24.40 per share, with a total value of $219,600.00. Following the acquisition, the director now directly owns 66,301 shares in the company, valued at $1,617,744.40. The disclosure for this purchase can be found here. Insiders have sold a total of 8,119,219 shares of company stock valued at $220,455,844 in the last quarter. 15.26% of the stock is currently owned by company insiders.
Several equities research analysts have recently weighed in on JUNO shares. Wedbush raised shares of Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 price target for the company in a research report on Tuesday, August 29th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $54.00 price target (up previously from $35.00) on shares of Juno Therapeutics in a research report on Tuesday, September 5th. Raymond James Financial, Inc. raised shares of Juno Therapeutics from a “market perform” rating to an “outperform” rating and set a $45.00 price target for the company in a research report on Tuesday, August 29th. Standpoint Research reaffirmed a “reduce” rating on shares of Juno Therapeutics in a research report on Thursday, August 31st. Finally, Vetr raised shares of Juno Therapeutics from a “sell” rating to a “hold” rating and set a $28.85 price target for the company in a research report on Monday, July 10th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $34.88.
TRADEMARK VIOLATION NOTICE: “Juno Therapeutics, Inc. (JUNO) Shares Bought by Utah Retirement Systems” was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.chaffeybreeze.com/2017/09/16/juno-therapeutics-inc-juno-shares-bought-by-utah-retirement-systems.html.
Shares of Juno Therapeutics, Inc. (JUNO) opened at 44.30 on Friday. The company’s 50-day moving average is $34.04 and its 200-day moving average is $27.13. Juno Therapeutics, Inc. has a 52-week low of $17.52 and a 52-week high of $47.00. The stock’s market cap is $4.65 billion.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. During the same quarter last year, the firm earned ($0.64) EPS. The company’s revenue was down 22.8% on a year-over-year basis. Equities analysts anticipate that Juno Therapeutics, Inc. will post ($3.12) EPS for the current year.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.